Brazikumab
Modify Date: 2024-04-11 22:43:06
Brazikumab structure
|
Common Name | Brazikumab | ||
|---|---|---|---|---|
| CAS Number | 1610353-18-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BrazikumabBrazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease[1]. |
| Name | Brazikumab |
|---|
| Description | Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-23:0.138 nM (Kd) |
| In Vitro | Brazikumab inhibits the binding of both recombinant and native IL-23 to its receptors stably expressed in COS cells with IC50s of 188 and 284 pM, respectively[1]. Brazikumab inhibits the production of IFN-γ in NK cells stimulated by human native or recombinant IL-23 (in association with IL-18) with IC50s of 238 and 93 pM, respectively[1]. |
| References |
| No Any Chemical & Physical Properties |